LILLY & Co ELI
CIK 59478 · Director, Chairman and CEO · last filed 2023-08-14
LILLY & Co ELI is a Director, Chairman and CEO who has filed 26 SEC Form 4 insider transactions across 10 companies since 2010. The most recent filing shows the insider bought $51.3M of SGTX on Aug 14, 2023. Across all open-market trades the lifetime net is +$1.57B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.91B across reported positions. 483 SEC filings were submitted jointly with LILLY ENDOWMENT INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
Filer Profile
DROP CODE 1094
INDIANAPOLIS, IN 46285
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Sigilon Therapeutics, Inc. (SGTX) Delisted | 10%+ Owner | 100 | $22.47 | $2.2K | $56.68M | 2 | 2023-08-14 |
| RNA | 10%+ Owner | 2,169,396 | $7.84 | $17.01M | $0 | 1 | 2020-06-16 |
| DERM | 10%+ Owner | 100 | $6.61 | $661 | $1.53B | 1 | 2020-02-20 |
| ELAN | 10%+ Owner | 0 | $22.14 | $0 | $0 | 1 | 2019-03-11 |
| ZYME | 10%+ Owner | 1,827,101 | $25.15 | $45.95M | -$15.35M | 14 | 2019-02-06 |
| CYPHERPUNK TECHNOLOGIES INC. (LPTX) Delisted | 10%+ Owner | — | $1.56 | — | $0 | 1 | 2018-08-13 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 100 | — | — | $0 | 1 | 2017-03-01 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 102,742 | $12.01 | $1.23M | $5.00M | 1 | 2016-04-14 |
| Receptos, Inc. (RCPT) Delisted | 10%+ Owner | 2,081,210 | — | — | $6.00M | 1 | 2013-11-21 |
| UTHR | 10%+ Owner | 5,251,394 | $541.70 | $2.84B | -$12.96M | 3 | 2011-07-06 |
Recent Filings
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-14 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Buy (P) | +3,436,986 | $51.28M | EDGAR |
| 2020-12-10 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Mixed | +2,744,443 | $5.40M | EDGAR |
| 2020-06-16 | RNA | Conv (C) | +2,169,396 | $0 | EDGAR |
| 2020-02-20 | DERM | Buy (P) | +81,852,050 | $1.53B | EDGAR |
| 2019-03-11 | ELAN | Disp (D) | −293,290,000 | $0 | EDGAR |
| 2019-02-06 | ZYME | — | — | $0 | EDGAR |
| 2019-02-04 | ZYME | Sell (S) | −250,000 | -$4.00M | EDGAR |
| 2018-11-08 | ZYME | Sell (S) | −700,000 | -$9.80M | EDGAR |
| 2018-09-26 | ZYME | Sell (S) | −2,027 | -$33.2K | EDGAR |
| 2018-09-20 | ZYME | Sell (S) | −6,870 | -$100.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.